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ABSTRACT
Autologous peripheral blood stem cell transplantation for multiple myeloma offers higher response rates and
improved survival compared with conventional chemotherapy. However, successful autografting requires effective
cytoreduction and rapid hematologic reconstitution. We conducted a prospective randomized clinical trial to assess
the efficacy of 2 cycles of priming chemotherapy with either granulocyte colony-stimulating factor (G-CSF) or
granulocyte-macrophage colony-stimulating factor (GM-CSF) for peripheral blood stem cell mobilization followed
by autologous transplantation. The major study end points were the comparative utility of G-CSF versus GM-CSF,
the percentage of patients achieving complete response after transplantation, and overall and progression-free
survival. Priming chemotherapy included cyclophosphamide (4 g/m2), mitoxantrone (8 g/m2 every day for 2 days),
and dexamethasone (20 mg/m2 every 12 hours for 2 days) followed by randomization to either G-CSF or GM-CSF
daily until completion of leukapheresis. Conditioning for transplantation included cyclophosphamide (75 mg/kg
every day for 2 days) plus total body irradiation (165 cGy twice daily for 3 days), and patients received maintenance
immunotherapy with interferon . Seventy-two patients were randomized, and 64 underwent autologous trans-
plantation. The median age at transplantation was 52 years, and the median time from diagnosis to transplantation
was 10 months; 58% of the patients had received >4 cycles of pretransplantation chemotherapy. The median
number of CD34 cells obtained after mobilization was 16.4  106/kg in the G-CSF arm versus 12.8  106/kg in
the GM-CSF arm (P .8). Neutrophil recovery was faster in the G-CSF group after both cycle 1 (median, 13 days
with G-CSF and 16 days with GM-CSF; P < .01) and cycle 2 (median, 13 days versus 17 days in the 2 groups,
respectively; P  .03). Although platelet recovery was similar after cycle 1, platelet recovery to >100000/L was
notably faster in the G-CSF group both after cycle 2 and after transplantation (P  .03). Response and overall and
disease-free survival were similar in both cohorts. Overall, 23% of the patients achieved a complete response after
priming chemotherapy, which improved to 33% after transplantation. An additional 47% attained a partial response
after transplantation, for a total response rate of 80%. With a median follow-up of 2 years (range, 0.7-8 years), the
overall survival was 88% (95% confidence interval [CI], 80%-96%) at 1 year and 65% (95% CI, 51%-79%) at 3
years. Progression-free survival was 73% (95% CI, 62%-84%) at 1 year and 40% (95% CI, 26%-54%) at 3 years.
Relapse or progressive disease was the most common cause of death (25 [83%] of 30 deaths). We conclude that
mobilization with chemotherapy plus G-CSF versus GM-CSF results in similar CD34 progenitor collections, even
in patients exposed to multiple cycles of alkylator-based chemotherapy. Earlier neutrophil and platelet recovery was
seen with G-CSF priming. Two cycles of priming chemotherapy plus autologous transplantation yields survival
rates similar to those in published reports, including those using tandem transplantation.
© 2004 American Society for Blood and Marrow Transplantation
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3NTRODUCTION
Therapy of multiple myeloma has been enhanced
y the application of autologous bone marrow trans-
lantation (BMT) and peripheral blood stem cell
PBSC) transplantation [1-3]. The chemotherapy and
adiotherapy responsiveness of myeloma cells has
een demonstrated in numerous studies, with high
esponse rates, complete response (CR) rates, and
ong-term survival reported in some patients with my-
loma [1-3]. These favorable results have been fol-
owed by investigation of sequential or tandem trans-
lantation attempting to further debulk residual
lonogenic myeloma cells, augment response rate, and
nhance long-term survival [4-6]. However, tandem
ransplantation with full-dose myeloablative therapy is
ore rigorous than a single transplantation effort and
an be performed for only 60% to 70% of the patients
ho are candidates for the tandem transplantation
rocedure [4-6].
We designed a less intensive approach by using 2
ycles of nonablative but highly myelosuppressive
riming chemotherapy supported with either granu-
ocyte colony-stimulating factor (G-CSF) or granulo-
yte-macrophage colony-stimulating factor (GM-
SF), designed to deplete the myeloma tumor burden
nd facilitate collection of satisfactory PBSC for cryo-
reservation. These 2 priming chemotherapy cycles
ere followed by high-dose chemotherapy and radia-
ion conditioning. The clinical toxicity, progenitor
ell yield, hematologic recovery, and outcomes of the
chemotherapy priming cycles; the autotransplanta-
ion course; and posttransplantation interferon main-
enance therapy are reported.
ETHODS
Transplant candidates had histologically proven
tage II or III multiple myeloma. Patients after initial
herapy were eligible with either responsive disease or
onresponsive disease. However, relapsed patients
ad to be objectively responding to salvage chemo-
herapy to be eligible for transplantation. Eligible pa-
ients were required to have satisfactory organ func-
ion and be at least 4 weeks from prior chemotherapy
6 weeks after nitrosourea therapy) before enrollment.
ll patients provided written, informed consent before
ny study procedures.
Seventy-two patients were enrolled between 1993
nd 2002. Patients underwent 2 cycles of priming
hemotherapy for tumor reduction and PBSC mobi-
ization. PBSC collections were performed after both
riming cycles irrespective of the stem cell dose col-
ected after the ﬁrst collection. Each cycle included
yclophosphamide 4 g/m2 intravenously (IV) over 2
ours on day 1, mitoxantrone (8 mg/m2 IV) over 1
our on day 1 and day 2, and dexamethasone (20 s
96g/m2 IV) every 12 hours for 4 doses on day 1 and 2.
he daily administration of cytokine (starting day 4)
as randomly assigned to either G-CSF (250 g/m2/d
ubcutaneously) or GM-CSF (250 g/m2/d subcuta-
eously) until PBSC collections were complete. Doses
f cytokine were rounded to commercially available
ial sizes (or multiplex) for each daily dose. PBSC
ollections were performed daily for 2 to 3 days after
eutrophil recovery to 700/L, aiming for a target
ollection of 5 million CD34 cells per kilogram
minimum of 2 million CD34 cells per kilogram).
fter PBSC collections for cycle 1, cytokines were
iscontinued for at least 72 hours, followed by cycle 2
obilization with the same chemotherapy and as-
igned cytokine, with additional aphereses after neu-
rophil recovery to 700/L. In case of inadequate
ollection of CD34 progenitors, after a rest period of
to 2 weeks and full hematologic recovery (absolute
eutrophil count [ANC] 1000/L, hemoglobin 9
/dL, and platelets 100000/L), recollection was
ttempted by using the randomized cytokine alone
dministered for 5 to 8 days before apheresis.
Patients were followed up daily in the outpatient
ransplant clinic. Patients received irradiated red
lood cell and platelet transfusion support for hemo-
lobin 8 g/dL and platelets 10000/L. Penicillin,
iproﬂoxacin, and ﬂuconazole were used for infection
rophylaxis. At the completion of priming cycle 2,
atients were re-staged. The pretransplantation con-
itioning included cyclophosphamide (75 mg/kg IV)
ver 2 hours on days 6 and 5, followed by frac-
ionated total body irradiation (165 cGy twice daily)
n days 3, 2, and 1 (total 990 cGy) with high-
nergy linear accelerator external beam irradiation.
atients ineligible for total body irradiation because of
retransplantation irradiation received cyclophospha-
ide (1.5 g/m2 IV daily for 4 days: days 6, 5, 4,
nd 3), carmustine (300 mg/m2 IV day 5), and
toposide (150 mg/m2 IV twice daily for 3 days: days
6, 5, and 4). On day 0, all previously collected
BSCs were thawed and infused, followed by initia-
ion of GM-CSF (200 g/m2/d) plus G-CSF (200
g/m2/d) for all patients. Stable patients were fol-
owed up in the outpatient BMT clinic from day 1
nless clinical complications (fever, sepsis, persistent
ausea/vomiting, or electrolyte disturbance) required
npatient hospital care. Patients were re-staged after
ransplantation at day 28 and day 100; at 3-month
ntervals during the ﬁrst follow-up year; and 6 months
hereafter.
All patients with adequate hematologic recovery
hemoglobin 9 g/dL, white blood cell count 2500/
L, ANC 1500/L, and platelets 100000/L) af-
er transplantation were started on maintenance im-
unotherapy with  interferon self-administered
ubcutaneously in escalating doses up to 3 million
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Autologous PBSC Transplantation in Multiple Myeloma
B/m2 per dose 3 times per week as tolerated indeﬁ-
itely until relapse or disease progression.
All available records were reviewed to assess the
requency of posttransplantation infections. Minor in-
ectious episodes not requiring microbiologic diagno-
is or antimicrobial therapy (upper respiratory tract
nfection) were not considered. However, docu-
ented infections associated with clinically compati-
le symptoms and microbiologic or virologic conﬁr-
ation were tabulated.
valuation of Response
Response was assessed after priming (before trans-
lantation), at days 28 and 100, and 6 months after
ransplantation. CR was deﬁned as the absence of
onoclonal gammopathy on serum or urine electro-
horesis and 5% plasma cells in the bone marrow.
artial response (PR) was deﬁned as a 50% decrease
n serum paraprotein, a 90% decrease in urinary ex-
retion of light chain paraprotein, or both. Smaller
ecreases were considered minimal response (MR).
table disease was deﬁned as values within 25% above
r below the original value at the time response was
ssessed. Relapse after CR was deﬁned as the reap-
earance of paraprotein or bone marrow plasma cell
nﬁltration or the appearance of new lytic lesions,
hereas progressive disease (PD) required a 50% in-
rease in measurable paraprotein. Posttransplantation
esponse could not be assessed in 2 patients who died
efore 28 days after autografting.
tatistical Analysis
The study was designed as a prospective random-
zed clinical trial. Seventy-two patients were enrolled
n the trial. Eight patients did not proceed to trans-
lantation and were excluded from subsequent post-
ransplantation analysis. Of 64 patients who pro-
eeded to transplantation, 31 were randomized to the
-CSF group and 33 to the GM-CSF group. Baseline
emographic data, laboratory data, stage of disease at
iagnosis, pretransplantation chemotherapy, response
o initial chemotherapy, dates of diagnosis and treat-
ent, complications, survival times, causes of death,
nd relapse were prospectively entered into the Uni-
ersity of Minnesota Blood and Marrow Transplant
atabase, which contains prospectively collected data
n all patients treated at our center. Data collection
nd entry were performed by trained personnel.
hese data were supplemented by individual chart
eviews for hematologic recovery after priming che-
otherapy and after transplantation; complications;
oxicity; maintenance immunotherapy with  inter-
eron; and veriﬁcation of response, relapse, and pro-
ression. Adequacy of randomization to balance po-
entially important clinical prognostic factors was p
B&MTested by 2 analysis for categorical variables or by t
est for continuous variables.
esponse to Therapy
The Pearson 2 test was used to compare the
roportion of subjects who attained a response in each
roup (CR or PR versus MR, stable disease, or pro-
ression). Log-rank comparisons were performed for
rogenitor yield and time to hematologic recovery
fter priming and after transplantation.
urvival
Patient survival was determined by using the
aplan-Meier estimation [7] with 95% conﬁdence in-
ervals (CI) derived from SEs. Patients were censored
t the date of last contact. Comparison of survival
etween the 2 treatment groups was performed by
sing Kaplan-Meier plots and log-rank tests.
redictors of Mortality
Potential factors associated with effects on mor-
ality were studied. The Kaplan-Meier product-limit
ethod was used to compare survival and progres-
ion-free survival in the subsets, and the Cox regres-
ion model [8] was used to assess the independent
ffect of the predictors on survival. A stepwise regres-
ion with forward selection was used, with a signiﬁ-
ance level of 0.1 used to enter into the model and
.15 to stay in the model. Cumulative incidence rates
9] were used to estimate the probability of relapse or
rogression after transplantation.
nfections
To account for multiple events, incidence density
as used to describe the total rate of infections. Den-
ity incidence was deﬁned as the total number of
nfections per 1000 patient-days (p-d).
ESULTS
Seventy-two patients were enrolled in the trial.
ight patients did not proceed to transplantation and
ere excluded from subsequent analysis. One declined
ransplantation after priming chemotherapy, and 7 (3
ho received G-CSF and 4 who received GM-CSF)
id not mobilize sufﬁcient progenitor cells to proceed
ith transplantation. Thirty-ﬁve were randomized to
he G-CSF group, and 37 received GM-CSF. As
hown in Table 1, the clinical characteristics of the
atients were well balanced between the 2 randomized
ohorts. The median age at transplantation was 52
ears in the GM-CSF group versus 50 years in the
-CSF group. Forty-three patients (60%) underwent
utotransplantation after initial therapy, whereas 29
atients (40%) received transplantation after salvage
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3hemotherapy. Five had pretransplantation irradia-
ion, which precluded total body irradiation.
The 64 patients who proceeded to transplantation
ncluded 11 who had received 3 to 15 cycles of prior
lkylator therapy. The 7 others (excluded from anal-
sis) who mobilized insufﬁcient CD34 progenitors
1.2  106/kg) to proceed with transplantation had
eceived 2 to 16 cycles (median, 7 cycles) of prior
hemotherapy, and the median time from diagnosis to
tudy entry was 1.1 years (range, 0.5-4.2 years): this
as not dissimilar to the data of the 64 good mobilizers.
Seventy-two patients underwent 1 cycle of prim-
ng chemotherapy. The second cycle of priming che-
able 1. Demographic Characteristics
Variable
ge, y, median (range)
At diagnosis
At transplantation
ex, n (%)
Male
Female
g subtype, n (%)
IgG
IgA
Light chain
Nonsecretory myeloma
Multiple plasmacytomas
isease status at study entry, n (%)
Responsive disease (CR  PR)
Nonresponsive disease
tage at diagnosis, n (%)
I
II
III
aseline laboratory values at diagnosis
Hemoglobin, g/dL median (range)
2 microglobulin, mg/L median (range)
one marrow plasmacytosis (% cells)
<30
>30
erum calcium, mg/dL, median (range)
erum creatinine, mg/dL, median (range)
o. sites of lytic lesions (%)
0
1-3
>3
ransplantation after
Initial therapy, n (%)
Salvage therapy, n (%)
retransplantation chemotherapy cycles
<4, n (%)
>4, n (%)
Median (range)
retransplantation chemotherapy regimens, n (%)
1
>2
ime from diagnosis to transplantation, y, median (range)
osttransplantation follow-up, y, median (range)
g indicates immunoglobulin; CR, complete response; PR, partial re
and Wilcoxon rank sum tests for continuous variables.otherapy was deferred in 14 (19.4%) patients sec- i
98ndary to extremely poor collections (1.0 106/kg),
oxicity, and patient refusal. The median number of
D34 cells collected after the ﬁrst cycle of priming
hemotherapy was similar in both groups (12.8 
06/kg (range, 0.4-94.5  106/kg) in the GM-CSF
roup versus 16.4 106/kg (range, 1.1-71.7 106/kg)
n the G-CSF group; P 	 .8; Figure 1). Notably,
espite prompt hematologic recovery during cycle 2,
he CD34 progenitor yield was very low in both
andomized cohorts (median, 0.3  106/kg). As
hown in Figure 2, recovery to a neutrophil count of
500/L for 2 days was 3 to 4 days quicker in the
-CSF group after both cycle 1 and cycle 2 of prim-
M-CSF (n  37) G-CSF (n  35) P Value
51.8 (39.8-63.6) 50.2 (30.4-63.6) .70
52.5 (40.5-64.2) 52.4 (31.3-64.6) 1.00
20 (54.0) 21 (60) .60
17 (46.0) 14 (40)
16 (43.2) 24 (68.6) .04
11 (29.8) 2 (5.7)
9 (24.3) 8 (22.9)
0 (0.0) 1 (2.8)
1 (2.7) 0 (0)
31 (83.8) 31 (88.5) .60
6 (16.2) 4 (11.5)
2 (5.4) 2 (5.7) .60
10 (27.0) 5 (14.3)
25 (67.6) 28 (80.0)
9.5 (3.9-14.6) 9.35 (4-14.5) .87
3.15 (0.8-10.7) 3.3 (1.3-14.3) .60
13 (35.1) 10 (29.0) .60
24 (64.9) 25 (71.0)
10.0 (8.2-14) 10.5 (8-12.5) .50
1.45 (0.8-7.8) 1.4 (0.6-8.4) .80
5 (13.5) 7 (20.0) .30
12 (32.4) 8 (22.9)
20 (54.1) 20 (57.1)
24 (64.9) 19 (54.3) .40
13 (35.1) 16 (45.7)
16 (43.2) 12 (34.3) .30
21 (56.8) 23 (65.7)
5 (2-16) 5 (3-15) .60
24 (64.9) 22 (62.9) .90
13 (35.1) 13 (37.1)
0.73 (0.36-4.23) 1.01 (0.42-6.82) 1.0
2.0 (0.7-8) 2.0 (1-8) 1.0
. P values represent 2 tests of signiﬁcance for categorical variablesG
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Bedian of 16 days in the GM-CSF group versus 13
ays in the G-CSF group after cycle 1 (P  .01) and
t a median of 17 and 13 days (P 	 .03), respectively,
fter cycle 2. The time to recovery to a platelet count
100000/L was similar in both groups after cycle 1.
owever, in cycle 2, platelet recovery was signiﬁcantly
elayed in the GM-CSF group, with 89% of GM-
SF patients having continuing thrombocytopenia
eyond 28 days, versus only 42% with G-CSF (P 
01). Delayed posttransplantation hematologic recov-
ry was not predicted by the CD34 dose of cells
ransfused. Adequate CD34 cell doses were infused
38.1-94.5 106/kg) in 4 patients in whom neutrophil
igure 1. CD34 cell mobilization. Median (range) CD34 cell
ounts (106/kg) are shown in the boxes. The whiskers represent
he outliers. Seven patients (4 in the GM-CSF cohort and 3 in the
-CSF cohort) did not collect sufﬁcient CD34 progenitors.
igure 2. Hematologic recovery after priming chemotherapy. Sho
500/L for 2 days after cycle 1 and 2 and (C and D) platelet rec
ycles of priming chemotherapy.
B&MTecovery was delayed to15 days after transplantation
3 in the GM-CSF group and 1 in the G-CSF group).
imilarly, adequate CD34 doses (4.17-12.02  106/
g) were transfused in 10 patients (6 in the GM-CSF
roup and 4 in the G-CSF group) in whom platelet
ecovery to 50000/L was delayed beyond 30 days
fter transplantation.
After a median of 36 days (range, 18-74 days) from
nitiation of cycle 2, 61 patients underwent autotrans-
lantation. The median time from the initiation of
ycle 1 to transplantation was 63 days (range, 46-99
ays). Two patients underwent cytokine-primed sup-
lemental PBSC collections and underwent transplan-
ation on days 96 and 99. Transplantation was delayed
eyond 100 days in 3 other patients. Two patients
GM-CSF group) developed respiratory syncytial vi-
us pneumonitis (1 with enterococcus bacteremia and
with aspergillus pneumonia plus renal failure), which
equired ventilator support and prolonged hospitaliza-
ion. These patients then underwent transplantation
n day 370 and 391 after priming cycle 1. The third
atient (G-CSF group) had inadequate PBSC collec-
ions after 2 priming cycles and later successfully un-
erwent cytokine-only–primed PBSC collections and
hen transplantation on day 322.
All but 5 patients received cyclophosphamide and
ractionated total body irradiation as their pretrans-
lantation conditioning; the others received chemo-
the proportion of patients with (A and B) neutrophil recovery to
o 100000/L after cycle 1 and 2. Fifty-eight patients received 2wn are
overy t399
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4herapy only. Patients had prompt hematologic recov-
ry (Figure 3), with neutrophil recovery at a median of
0 days (range, 7-45 days) after transplantation and
ed blood cell independence at a median of 14 days
range, 0-108 days). Similarly, prompt recovery of
latelets to 20000/L and 50000/L was seen in
ost patients in both groups: it occurred at a median
f 11 days (range, 0-365 days) and 15 days (range,
-365 days), respectively. Only 2 patients had pro-
onged severe thrombocytopenia (platelet count
20000/L) beyond 180 days after transplantation (1
ach in the G-CSF and GM-CSF groups). However,
latelet recovery to100000/L was signiﬁcantly de-
ayed in the GM-CSF group. Five patients receiving
-CSF versus 13 receiving GM-CSF remained
hrombocytopenic (platelet count 100000/L) be-
ond 180 days after transplantation (P 	 .03).
yeloma Response to Therapy
After 2 cycles of priming chemotherapy, 15 (23%)
atients had attained a CR, 19 (30%) patients had
igure 3. Engraftment after transplantation. Shown are neutrophil
ransfusion support for 3 months (B); and platelet recovery to 50chieved a PR, 22 (34%) patients had an MR, 7 (11%)
00atients had stable disease, and 1 (2%) patient had PD
Table 2). By 6 months after transplantation, 21 (33%)
atients were in CR, 30 (47%) patients were in PR, 9
atients (14%) had MR, and 2 patients (3%) had PD
Table 3). Response could not be assessed in 2 patients
ecause of early (28 days) peritransplantation mor-
ality. Therefore, by 6 months after transplantation,
1 (80%) of 64 of patients responded (CR or PR) to
he serial cycles of priming and transplantation therapy.
y to 500 for 2 days (A); hemoglobin recovery 8.0 g/dL without
and 100000/L (C and D, respectively).
able 2. Response to Priming Chemotherapy
Response
GM-CSF
n (%)
G-CSF
n (%) P Value*
R 9 (27) 6 (19) .60
R 11 (34) 8 (26)
inimal response 10 (30) 12 (39)
table disease 3 (9) 4 (13)
rogression 0 (0) 1 (3)
R indicates complete response; PR, partial response.
Chi-square analysis of signiﬁcance between CR plus PR versus therecoverother response groups combined.
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Bosttransplantation  Interferon
Stable patients with satisfactory hematologic re-
overy (ANC 1500/L and platelets 100000/L)
eceived interferon in escalating doses as tolerated up
o 3 million U/m2 subcutaneously 3 times weekly.
hirty-four (53%) patients received interferon start-
ng at a median of 112 days (range, 29-501 days) after
ransplantation. Four patients discontinued the med-
cation at 100 days after transplantation secondary
o side effects (ﬂulike symptoms, headache, and
hrombocytopenia). Two additional patients discon-
inued interferon on days 116 and 153 because of
epression. Three patients had PD at 1 year and
topped interferon. Twenty-ﬁve (74%) patients re-
ained on interferon at the end of 1 year after trans-
lantation. The median stable dose of interferon in
hese patients was 3 million units (range, 0.5-5.7 mil-
ion U) 3 times per week. Fourteen patients discon-
inued the medication at a median of 780 days (range,
06-1468 days) secondary to PD.
urvival
After a median follow-up of 2 years (range, 0.7-8.0
ears), 34 (53%) patients are alive, and 19 (30%) are
rogression free. As shown in Figure 4, the Kaplan-
eier probability of overall survival was 88% (range,
0%-96%) at 1 year and 65% (range, 51%-79%) at 3
ears, whereas the probability of progression-free sur-
ival was 73% (range, 62%-84%) at 1 year and 40%
range, 26%-54%) at 3 years. The median overall and
able 3. Response to Transplantation
Response GM-CSF G-CSF P Value*
R, n (%) 13 (39) 8 (28) .60
R, n (%) 16 (49) 14 (48)
inimal response, n (%) 3 (9) 6 (21)
rogression, n (%) 1 (3) 1 (3)
ime to progression, y,
median (range) 1.0 (0.18-3.3) 1.6 (0.19-5.8)
R indicates complete response; PR, partial response.
Chi-square analysis of signiﬁcance between CR plus PR versus the
other response groups combined.Figure 4. Survival and progression-fre
B&MTrogression-free survival was 53 and 29 months, re-
pectively. Thirty patients have died. Relapse/pro-
ressive myeloma was the most common cause of
eath (n 	 25; 83%). The cumulative incidence of
elapse or progression was 22% (95% CI, 12%-32%)
t 1 year and 48% (95% CI, 33%-63%) at 3 years
Figure 5). Five patients died of causes other than
elapse. Only 3 patients died of peritransplantation
omplications before day 100 after transplantation.
ne died of veno-occlusive disease on day 14; 2
eveloped viral pneumonitis (1 respiratory syncytial
irus along with aspergillus lung disease and 1 inﬂu-
nza B) and died on day 15 and day 93, respec-
ively. The cumulative incidence of nonrelapse mor-
ality was 3% (95% CI, 0%-7%) at 3 months and 5%
95% CI, 0%-10%) at 1 year. One patient developed
myelodysplastic syndrome (MDS) and died second-
ry to toxoplasmosis and bacterial infection. One pa-
ient underwent an allogeneic transplantation for
DS at 27 months after autologous transplantation
nd died 3 months later of acute respiratory distress
yndrome and acute graft-versus-host disease. Among
hese 5 patients, the median time from diagnosis to
ransplantation was 1.6 years (range, 0.7- 6.8 years),
nd 3 patients underwent transplantation 1 year
rom diagnosis. All patients had received 4 cycles of
retransplantation chemotherapy (median, 7; range,
-10), and 3 had relapsed and been treated with 2
egimens of pretransplantation chemotherapy.
redictors of Progression-Free Survival
In multiple regression analysis (Table 4), the risk
f relapse or death was 2.0 times higher (95% CI,
.1-3.9; P 	 .03) in patients who had received 4
ycles of prior chemotherapy. The relative risk was
imilarly high (2.2; 95% CI, 1.1-4.5; P 	 .03) in
atients who did not attain a CR after transplantation
Table 4). Patients who did not receive interferon also
ad a higher risk of relapse or death (signiﬁcant in
nivariate analysis; data not shown), but this was not
ndependently signiﬁcant in predicting progression-
ree survival.e survival after transplantation.
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4nfections
Infections were frequent in the peritransplantation
eriod. A high density incidence of all infections (4.1/
000 p-d from 0 to 24 months after transplantation)
as observed (approximately 1.3 infections per pa-
ient). Across all time periods, bacterial infections
ere the most common (2.5/1000 p-d). However,
iral (1.1/1000 p-d) and fungal (0.5/1000 p-d) infec-
ions were also seen. Overall, the density incidence of
nfections was highest in the 0- to 6-month period,
hen all infections and bacterial infections were seen
t a rate of 9/1000 p-d and 6/1000 p-d, respectively.
his represents every patient in the 0- to 6-month
eriod developing a minimum of 1.5 infections; how-
ver, excess infections continued even late after trans-
lantation. The rate of infection was similar in the 2
andomized cytokine priming groups (data not
hown).
yelodysplastic Syndrome
Four patients developed MDS between 12 and 24
onths after transplantation. In these, the interval
rom diagnosis to transplantation ranged from 1.3 to
.8 years, and all 4 patients had received 8 cycles of
nitial chemotherapy before transplantation. All 4 pa-
ients had relapsed before transplantation and had
eceived a median of 9 (range, 7-11) cycles of melpha-
an-based pretransplantation chemotherapy. The cu-
ulative incidence of MDS was 2% at 1 year and 11%
verall. All 4 patients died at a median of 3.2 years
range, 1.5-5.1 years) after transplantation. One pa-
ient died secondary to toxoplasmosis along with bac-
erial infection. Two patients relapsed and died sec-
ndary to myeloma plus MDS. Another patient
ubsequently underwent allotransplantation for MDS
nd died secondary to acute graft-versus-host disease
nd acute respiratory distress syndrome.
ISCUSSION
Multidrug chemotherapy plus either G-CSF or
igure 5. Cumulative incidence of relapse/progression after trans-
lantation.M-CSF yielded mobilization of an adequate graft
02or autotransplantation in 90% of myeloma patients,
ven those who had received extensive prior therapy
ith stem cell–toxic drugs. Extensive pretransplanta-
ion chemotherapy has been cited as a barrier to suc-
essful graft collection. Our data suggest that for most
atients, chemotherapy plus cytokine mobilization can
vercome even extended exposure to pretransplanta-
ion alkylator therapy and can yield a suitable graft for
0% of patients. In our study, the randomized com-
arison of G-CSF versus GM-CSF demonstrated a
imilar CD34 cell yield with either cytokine for
riming. It is important to note, however, that hema-
ologic recovery was superior with G-CSF for the
ytokine after priming chemotherapy and that G-CSF
riming was also associated with superior platelet re-
overy after transplantation. A dose of 250 g/m2/d
or both G-CSF and GM-CSF was used. A similar and
dequate CD34 cell yield was obtained by using
hese doses with either cytokine. Despite adequate
D34 counts, neutrophil recovery was signiﬁcantly
elayed in the GM-CSF group after both cycle 1 and
ycle 2, and platelet recovery was signiﬁcantly delayed
n the GM-CSF group after the second cycle of prim-
ng and after transplantation. In addition, delayed he-
atologic recovery was not predicted by the CD34
ells transfused: adequate CD34 cells were infused in
patients with delayed neutrophil recovery after
ransplantation and in 10 patients with delayed plate-
et recovery after transplantation.
Despite prompt hematologic recovery after cycle
, the CD34 progenitor yield was very low in both
roups. This may reﬂect microenvironmental damage
nduced by the ﬁrst mobilization or stem cell/progen-
tor cell depletion associated with serial alkylator-
ased priming cycles.
Previous reports have described a median survival
f 43 to 68 months [1-6,10] and progression-free sur-
ival of 21 to 43 months after autotransplantation in
atients with multiple myeloma [1,3,4]. In a recent
tudy, Child et al. [11] reported a median survival of
4 months (versus 42 months; 31 versus 19 months for
edian progression-free survival) for high-dose ther-
py and autografting (versus conventional therapy,
espectively) in a randomized trial for newly diagnosed
ntreated patients with myeloma.
Tandem transplantation has been reported to
able 4. Predictors of Relapse/Progression-Free Survival: Multivariate
nalysis
Predictor RR CI P Value
4 cycles of pretransplantation
chemotherapy 2.0 1.1-3.9 .03
o CR after transplantation 2.2 1.1-4.5 .03
andomized cytokine (GM-CSF vs. G-CSF) 1.5 0.7-3.3 .30
hown is the relative risk (RR) (95% conﬁdence interval [CI]) of
progression/relapse or death after autologous transplantation.
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Autologous PBSC Transplantation in Multiple Myeloma
Bhow highly favorable results when it is incorporated
nto the initial therapy of patients with myeloma,
esulting in 48% CR and 58% surviving at 5 years
rom diagnosis [4]. A randomized comparison of sin-
le versus double transplantations in patients with
arly myeloma also showed superior results with dou-
le transplantations (the 7-year probability of overall
nd event-free survival was 42% and 20% versus 21%
nd 10%, respectively) [5]. However, the safety and
olerance of a second autologous transplantations are
ompromised in patients with relapsed myeloma who
ave undergone multiple cycles of pretransplantation
hemotherapy. Even when it is planned as part of the
nitial therapy, only 71% patients undergo the
lanned second (tandem) autograft [4].
Early transplantation with less pretransplantation
hemotherapy has generally been recommended for
atients with myeloma [2,6], and this is currently be-
ng tested in a US Intergroup trial. Our data demon-
trated in multiple regression analysis that achieve-
ent of a CR after transplantation and 4 cycles of
retransplantation chemotherapy were associated with
uperior survival. This conﬁrms earlier reports that
utotransplantation can produce extended disease
ontrol for a sizable fraction of patients, especially
hose with only limited pretransplantation therapy.
Overall, 4 patients developed MDS. All 4 patients
ad relapsed before transplantation and had been pre-
reated with multiple cycles of alkylator-based chemo-
herapy (median, 9), which likely contributed to the
igh incidence.
The cumulative incidence of transplant-related
ortality was 5% at 1 year. This may be a result of the
igh-risk population undergoing transplantation
60% with relapsed disease, with 1 year from diag-
osis to transplantation).
Posttransplantation interferon has been associated
ith improved disease-free survival [12]. In this study,
atients who received interferon had superior pro-
ression-free survival in univariate analysis, although
his was not independently signiﬁcant in multivariate
nalysis. Only 53% of patients received interferon,
lthough most tolerated it well and continued therapy
ell beyond 2 years after transplantation. Relapse re-
ained the most common cause of death in these
atients (83%). Additional posttransplantation thera-
ies are needed to extend response durations and pro-
ong survival.
Patients with myeloma have recognized immuno-
eﬁciency and a high risk of infection [13]. In this
tudy, a high density incidence of infections was seen.
he density incidence was highest in the 0- to
-month period, with a predominance of bacterial
nfections.
We report good tolerance of 2 cycles of intensive
hemotherapy plus cytokine mobilization of PBSCs in 1
B&MTatients with advanced myeloma. Thus, 3 sequential
ntensive treatment courses were administered (for all
ut 3 patients within 100 days), resulting in CR in
3% of patients after priming, which improved to
3% after transplantation. Median overall and pro-
ression-free survival were 53 and 29 months after
ransplantation, respectively. These data suggest that
equential cycles of intensiﬁed chemotherapy and au-
ografting can achieve good disease control and pro-
ong survival and may be a possible alternative to
andem transplantations in these patients.
Overall, we observed minimal morbidity and
rompt hematologic recovery during the 2 chemo-
herapy priming cycles and in both priming cycles. It
s important to note that the second mobilization cycle
ielded few CD34 cells and failed to substantially
nhance the graft progenitor content for nearly all
atients. Thus, a second chemotherapy priming cycle
s not indicated for mobilization of additional progen-
tors, at least with these medications and schedule.
owever, the overall utility of a second priming cycle
or added tumor reduction as a contributor to better
urvival and as a possibly safer substitute for tandem
ransplantation requires further study.
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